Interaction of PTEN and CDKN1B in Pca susceptibility
Interaction of PTEN and CDKN1B in Pca susceptibility
批准号:
7255626
负责人:
Jianfeng Xu
金额:
$38.17万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2009-06-30
关键词:
12p135&apos Untranslated RegionsAffectAllelesAnimalsBioinformaticsBiologicalBiological AssayBiologyCDKN1B geneCancer FamilyCodeCollectionComplexDNA SequenceDataDevelopmentDiseaseDisease regressionDisruptionElderlyElectrophoretic Mobility Shift AssayEventFamilyFamily memberFreezingFutureGenesGeneticGenetic Predisposition to DiseaseGenetic TranscriptionGenomeGenomicsGenotypeGerm-Line MutationHaplotypesHeterogeneityHumanHyperplasiaImmunohistochemistryIndividualInheritedInvestigationKnock-outKnockout MiceKnowledgeLinkLogistic RegressionsLuciferasesMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMethodsModelingMolecularMusMutationNucleic Acid Regulatory SequencesNumbersPTEN genePatientsPersonal SatisfactionPolymerase Chain ReactionPopulationPopulation StudyPredispositionPromoter RegionsProstateProstate carcinomaProstatic NeoplasmsProstatic hypertrophyProtein SplicingProteinsRegression AnalysisResearch PersonnelRiskRisk FactorsRoleScreening procedureSiteStandards of Weights and MeasuresStructureTestingTimeTissuesTitleTranscriptTumor SuppressionTumor Suppressor GenesUnited StatesVariantanalytical methodbasecancer riskcase controlcyclin-dependent kinase inhibitor 1Bdesignexperiencegene functiongene interactiongenetic linkage analysisinterestmRNA ExpressionmRNA Stabilitymalignant breast neoplasmmenmouse modelmutation carriernovelnovel strategiesprobandpromoterprotein expressionprotein functionsegregationtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer is the most common cancer among men in the United States and genetic susceptibility is one of the strongest risk factors for this disease. Although the roles of tumor suppressor genes such as PTEN and CDKN1B in tumorigenesis have been well established in multiple cancers, including prostate, studies that examined the independent effect of germline mutations of PTEN and CDKN1B on prostate cancer risk have been limited and generally unsuccessful. Recently, a mouse study clearly demonstrated that combinations of genetic effects at both Pten and Cdknlb, rather than a single gene, cause prostate cancer in mice. In addition, the linkage results from our genome-wide screen also demonstrated a strong interaction between the chromosomal regions at 10q23 (PTEN) and 12pl 3 (CDKNIB). We therefore hypothesize that the interaction of germline mutations in two tumor suppressor genes (PTEN and CDKNIB) affects individual susceptibility to hereditary and non-hereditary prostate cancer. Four specific aims are proposed to test this hypothesis: 1) To sequence the entire transcript and promoter regions of CDKNIB and potentially important regions of PTEN to identify mutations and sequence variants among 188 high risk HPC probands and perform bioinformatic analysis to predict the biological significance of the identified variants; 2) To assess the main effect of each gene and the interaction effect of the two genes in hereditary prostate cancer by testing for linkage and association of the identified mutations/sequence variants with prostate cancer in all 188 HPC families using one-locus and two-locus linkage and association analyses; 3) To assess the main effect of each gene and the interaction effect of the two genes in non-hereditary prostate cancer by testing for association between the identified mutations/sequence variants and prostate cancer in a case-control population using single SNP, haplotype, and MDR approaches; and 4) To evaluate the functional impact of the mutations/sequence variants by measuring the expression of mRNA and protein levels, and alteration in protein functions, for a subset of mutations/sequence variants that are implicated in linkage and association analyses. The results from this study are likely to significant advance our knowledge of prostate cancer risk and begin to explore the underlying biological mechanisms for any observed differences.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering novel designer biologics in plant cells for oral treatment of ulcerative colitis
-
批准号:10202300
-
项目类别:
-
资助金额:$39.52万
-
财政年份:2021
-
负责人:Jianfeng Xu
-
依托单位:
Clinical validity and utility of genomic targeted chemoprevention of PCa
-
批准号:7944011
-
项目类别:
-
资助金额:$200.64万
-
财政年份:2009
-
负责人:Jianfeng Xu
-
依托单位:
Clinical validity and utility of genomic targeted chemoprevention of PCa
-
批准号:7853457
-
项目类别:
-
资助金额:$197.23万
-
财政年份:2009
-
负责人:Jianfeng Xu
-
依托单位:
Confirmation of SNPs Associated with Aggressive PCa in a GWA Study
-
批准号:7756692
-
项目类别:
-
资助金额:$60.05万
-
财政年份:2008
-
负责人:Jianfeng Xu
-
依托单位:
Confirmation of SNPs Associated with Aggressive PCa in a GWA Study
-
批准号:7472728
-
项目类别:
-
资助金额:$67.96万
-
财政年份:2008
-
负责人:Jianfeng Xu
-
依托单位:
Confirmation of SNPs Associated with Aggressive PCa in a GWA Study
-
批准号:8015277
-
项目类别:
-
资助金额:$56.53万
-
财政年份:2008
-
负责人:Jianfeng Xu
-
依托单位:
Confirmation of SNPs Associated with Aggressive PCa in a GWA Study
-
批准号:7603059
-
项目类别:
-
资助金额:$60.38万
-
财政年份:2008
-
负责人:Jianfeng Xu
-
依托单位:
QTL mapping for genes regulating apoptosis capacity
-
批准号:7904112
-
项目类别:
-
资助金额:$24.79万
-
财政年份:2006
-
负责人:Jianfeng Xu
-
依托单位:
QTL mapping for genes regulating apoptosis capacity
-
批准号:7473113
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2006
-
负责人:Jianfeng Xu
-
依托单位:
QTL mapping for genes regulating apoptosis capacity
-
批准号:7664549
-
项目类别:
-
资助金额:$22.32万
-
财政年份:2006
-
负责人:Jianfeng Xu
-
依托单位:
Interaction of PTEN and CDKN1B in Pca susceptibility
-
批准号:6954721
-
项目类别:
-
资助金额:$27.08万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Interaction of PTEN and CDKN1B in Pca susceptibility
-
批准号:7460819
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Association of inflammatory genes and prostate cancer
-
批准号:7452328
-
项目类别:
-
资助金额:$44.12万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Interaction of PTEN and CDKN1B in Pca susceptibility
-
批准号:7122788
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Association of inflammatory genes and prostate cancer
-
批准号:6952298
-
项目类别:
-
资助金额:$50.38万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Association of inflammatory genes and prostate cancer
-
批准号:7125154
-
项目类别:
-
资助金额:$44.93万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Association of inflammatory genes and prostate cancer
-
批准号:6828454
-
项目类别:
-
资助金额:$52.29万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Association of inflammatory genes and prostate cancer
-
批准号:7255604
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Interaction of PTEN and CDKN1B in Pca susceptibility
-
批准号:6869425
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2004
-
负责人:Jianfeng Xu
-
依托单位:
Mapping Prostate Cancer Susceptibility Genes at 8p22-23
-
批准号:6681910
-
项目类别:
-
资助金额:$29.66万
-
财政年份:2003
-
负责人:Jianfeng Xu
-
依托单位:
国内基金
海外基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
-
批准号:81300507
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2013
-
负责人:陈黎
-
依托单位: